Fig. 7. CISP enhanced anti-tumor immunity in mice bearing colon cancer.

a Schematic illustration showing the experiment process. Red arrows indicate the administration of nanomedicines. The dosage of SR-717 is 10 mg/kg. b Flow-cytometric analysis of CD44⁺PD-L1⁺ cells in MC38 tumors on day 18 (n = 4 mice). c Flow-cytometric analysis of CD3⁺CD8⁺ cells in MC38 tumors (n = 4 mice). d Flow-cytometric analysis of CD69⁺ cells in CD8 T cells in MC38 tumors (n = 4 mice). e Flow-cytometric analysis of Granzyme B⁺ cells in CD8 T cells in MC38 tumors (n = 4 mice). f Flow-cytometric analysis of Ki67⁺ cells in CD8 T cells in MC38 tumors (n = 4 mice). g Flow-cytometric analysis of CD3⁺CD4⁺ cells in MC38 tumors (n = 4 mice). h Flow-cytometric analysis of Foxp3⁺ cells in CD4 T cells in MC38 tumors (n = 4 mice). i Tumor growth curve of mice bearing MC38 tumors. Red arrows indicate the administration of nanomedicines (n = 7 mice). j Survival curve of mice bearing MC38 tumors (n = 7 mice). Data represent mean ± SEM (b–i). Statistical significance was determined by one-way ANOVA test in b–h and it was two-sided and adjustments were made for multiple comparisons. Statistical significance was determined by two-way ANOVA test in i, and it was two-sided and adjustments were made for multiple comparisons. Survival was measured using the Kaplan-Meier method and statistical significance was calculated by log-rank test in j. Source data are provided as a Source Data file. QFN Quercetin-ferrum nanoparticles, QFN₇₁₇ QFN loaded with SR-717, nCSP normal-Cholesterol cell membrane-coated QFN₇₁₇, CSP low-cholesterol membrane-coated QFN₇₁₇, nCISP normal-Cholesterol cell membrane-coated ICB agent and QFN₇₁₇, CISP low-cholesterol membrane-coated ICB agent and QFN₇₁₇, CIP low-cholesterol membrane-coated ICB agent and QFN.